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1. INTRODUCTION 
The Welsh Institute for Health and Social Care (WIHSC), University of South Wales, was 
commissioned by the Welsh Government to contribute to the review of the All Wales Medicines 
Strategy Group (AWMSG) by engaging with a range of key stakeholders.  
ABOUT AWMSG 
AWMSG is a Welsh Government Sponsored Advisory Body. It has a constitution1 within which is 
described their ‘Roles and Responsibilities’ which are germane to the review: 
The Committee shall advise the Welsh Ministers on strategic developments in prescribing as 
outlined in the AWMSG Medicines Strategy for Wales, including:  
 forecast developments in healthcare which involve the use of medicines, to advise on the 
potential impact for the NHS of such developments and strategically plan for their impact 
within the available resources. The AWTTC will work in conjunction with the National 
Horizon Scanning Centre and the Pharmaceutical Industry, Research and Ethics 
Committees to inform the AWMSG of such developments.  
 advise on the availability of relevant new medicines/formulations, or of existing medicines 
with new indications, and on the cost implications of making these medicines routinely 
available on the NHS. This will include making interim recommendations ahead of 
appraisal by NICE. The Group should complement and support the work of NICE and not in 
any way duplicate or conflict with its work.  
 advise Welsh Government on the development of a consistent cost-effective medicine 
strategy for Wales, (with consideration to matters such as pharmaceutical developments, 
NICE guidance, National Service Frameworks, Welsh demography and epidemiology). 
 advise Welsh Government on how the Health Boards and other relevant organisations 
might implement the advice and strategy within the financial constraints placed upon 
them. Monitor and review the approved strategy, responding promptly to national 
changes in NHS policy that will affect prescribing and medicines management locally, 
including NICE guidance and National Service Frameworks, and advise Welsh Government 
accordingly.  
 review the roles of Medicines and Therapeutic Committees/Prescribing Advisory Groups 
within Local Health Boards.  
 where appropriate, advise Welsh Government on areas where legislative changes would 
support the development of prescribing and medicines management initiatives.  
 advise the Welsh Government on when medicines management policies / formularies and 
guidelines can be best co-ordinated. 
 make recommendations to Welsh Government to assist in the resolution of problems 
relating to prescribing at the interface between primary care, acute services, specialised 
and tertiary services, and social care.  
                                                          
1 http://awmsg.org/docs/awmsg/awmsgdocs/AWMSG%20Constitution.pdf  
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 receive for consideration, documents or issues referred to it by Welsh Government for 
Wales and other stakeholders, and advise Welsh Government accordingly.  
 act as a focus for developing and refining local professional opinion on medicines, 
therapeutics and associated prescribing issues, including risk management, and to convey 
such opinions through appropriate mechanisms.  
 advise Welsh Government on how consumer groups might be engaged to discuss 
consumer expectations and their impact on prescribing and medicines management.  
 produce an annual report for review by Welsh Government. 
 highlight to the Welsh Ministers, through the Chief Medical Officer or Chief 
Pharmaceutical Officer, issues concerning the maintenance and development of health 
services and health issues in Wales generally.  
TERMS OF REVIEW 
The following is taken from the Welsh Government setting out the Terms of the Review: 
Background 
2017 marked the 15th anniversary of the All Wales Medicines Strategy Group (AWMSG) and 2018 
was the 70th anniversary of the NHS. The NHS in Wales has changed dramatically over the past 15 
years, as has the development of new medicines and technology to treat our population.   
From January 2019 a new voluntary scheme for branded medicines pricing and access has been 
introduced, replacing the Pharmaceutical Price Regulation Scheme (PPRS).  Under the agreement, 
the National Institute for Health and Care Excellence (NICE) will increase its appraisal capacity to 
appraise all new active substances and significant extensions to marketing authorisations by April 
2020.   
This clearly has implications for the future role of the AWMSG in appraising new medicines and 
whether there is a need for a change of focus from appraisal of medicines to supporting NHS 
Wales’ efforts to improve medicines related outcomes 
Since the AWMSG was established in 2002 there has been no formal review of the services which 
they provide. In comparison the National Institute of Clinical Excellence (NICE), as an arms-length 
body, has been subjected to a triennial review by the Department of Health and Social Care. 
In the light of the significant changes in the landscape and in terms of good governance and 
funding process, it is, therefore, a timely opportunity to review the AWMSG.   
Terms of the review 
The terms of the review are to consider, review and report on: 
 the role of AWMSG in supporting the future delivery of Welsh Government and NHS Wales’ 
priorities; 
 the current relationship between AWMSG and NICE in light of plans to expand NICE’s 
appraisal role; 
 the balance between various functions carried out by the AWMSG, for example between 
appraisal of new medicines and optimising medicine use; 
 an understanding of how current funding reflects the balance of functions and whether this 
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reflects priorities now and for the future; 
 value for money and scope for efficiencies; 
 organisational governance and scrutiny, and the effectiveness of the current hosting 
arrangements within Cardiff and Vale UHB; 
 effectiveness, outputs and benefits; 
 AWMSG’s capacity and capability, both in terms of staffing and leadership, to respond 
effectively to future demands and the changing environment. 
APPROACH 
Based on the eight areas above, and in the context of the current roles and responsibilities of 
AWMSG, we have undertaken a review of the workings of the Committee. There were two 
strands to this.  
Firstly, the Welsh Government received 11 responses to its formal consultation process. We have 
reviewed these consultation responses.  
Secondly, in addition to these responses, this review draws on 40 semi- structured telephone and 
face-to-face interviews and three group discussions that were held between March and April 
2019 as described below: 
 
Respondent category No. of interviews 
No. of group 
respondents 
Total no. of 
respondents 
NHS 15 - 15 
AWMSG committee 
members 
3 - 3 
AWTTC staff - 7 7 
Other stakeholders2 6 - 6 
Citizens - 6 6 
Pharmaceutical industry 
representatives 
3 - 3 
TOTAL 40 
 
The schedule of questions that was used in the interviews and discussions detailed above drew 
heavily on the eight issues identified under the terms of review. Each of the respondents was 
assured that their responses would not lead to them being identified in any way, and that their 
words would not be quoted directly in the report. The interviews typically lasted between 30 and 
                                                          
2 These included a number of contributions from organisations from both inside and outside of Wales, including 
NICE. 
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45 minutes. We were also provided with supplementary written information by some 
interviewees, which has also been reviewed. 
NOTE ON TERMS 
It should be noted that there was a certain slippage in the way that terms were used throughout 
the interviews and discussions which has a particular relevance for two phrases: 
1. AWMSG – it was clear that when people used the acronym AWMSG they did not all mean 
the same thing. The vast majority of respondents used the term to refer to both AWMSG 
and AWTTC simultaneously and interchangeably. Therefore we use AWMSG/AWTTC 
throughout this document as this is what was implied by respondents; and 
2. Medicines management – we recognise the important difference that exists between the 
concept of medicines management and medicines optimisation, but again respondents 
used these phrases interchangeably. As such, when medicines management is used in this 
document, it includes both management and optimisation. 
REPORT STRUCTURE 
Over a short time period, this project that engaged with a broad range of people who are 
stakeholders or staff of AWMSG/AWTTC. The review team3 feel that this sample of people 
represents a robust cross-section of opinion on the work of the organisation. 
In Chapter 2 – Findings, for each item of the Terms of Reference we gathered and arranged 
evidence under three headings. “What people told us” identifies in respondents’ words the main 
issues they felt needed consideration.  As responses came from a range of stakeholders with 
different interests, we analysed these and provide for the reader the range and weight of opinion 
under the heading “Spectrum of Opinion”.  Finally, under “Conclusions” we have summarised 
where, on balance of the views expressed, we believe the key organisations should focus their 
attention. 
In Chapter 3 – Areas for Further Consideration, we have done two things.  First, given the range 
of evidence gathered in Chapter 2, we have distilled it into five strategic issues we believe the 
Welsh Government should deliberate upon when considering the future direction of AWMSG.  
Second, to provide a focus on how these issues can be taken forward into a clear plan for action 
we offer a set of ‘test questions’.  These are designed to help work through the key decisions 
required to establish clarity on a future direction.  
The structure of the report follows with a series of Findings structured against the eight Terms of 
Review. The report then proceeds to identify Areas for Further Consideration, which are borne 
out of our data and are written as a positive contribution to the way in which AWMSG/AWTTC 
might address the issues raised in the Terms of Review, and the responses given to us in respect 
of these issues.  
                                                          
3 More on the background and experience of the team can be found at: https://wihsc.southwales.ac.uk/team-
members/  
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2. FINDINGS 
This chapter presents the findings of our work based on the data we have collected. What 
follows is a discussion of each of the eight identified Terms of Review, providing the main issues 
that were raised in the interviews/discussions, the spectrum of opinion offered by respondents, 
and a conclusion about each. 
Before engaging with the detail of the findings, it is important to state that in the view of the vast 
majority of respondents, AWMSG/AWTTC needs to continue to play a role but needs to change 
in order to do this effectively.  It was especially well-respected for the work that it does in 
respect of the Health Technology Appraisals (HTAs) that it undertakes. However, there is much to 
be done, as below, against the eight areas that were identified in the Terms of Review. The case 
for change is remarked upon by the respondents, who simultaneously value the role that it 
performs but who recognise that the organisation needs to develop and transform as the context 
within which it operates evolves. 
2.1 THE ROLE OF AWMSG IN SUPPORTING THE FUTURE DELIVERY OF 
WELSH GOVERNMENT AND NHS WALES’ PRIORITIES 
What people told us 
 The balance between supporting the Minister by providing an arm’s length, independent 
strategic response to medicines access issues (e.g. through appraisals) and offering more 
practical operational support to the service on a range of medicines management issues 
including implementation and service change. 
 The as yet unknown impact of proposed NICE changes on AWMSG/AWTTC’s end to end 
appraisals process and the need to be cautious in dismantling AWMSG/AWTTC’s highly 
valued expertise prematurely, and how transition to the new arrangements will be managed. 
 The value that would be derived from using AWMSG/AWTTC’s expertise in improving the 
service’s response to commercial arrangements and the service implications of horizon 
scanning. 
 The potential AWMSG/AWTTC role in taking their advice into the service and supporting 
implementation. 
Spectrum of opinion 
The majority value both the strategic role in supporting market access (which includes HTAs) and 
the more operational medicines management role and most comment positively on the quality 
of the work produced.   
There is a division with those concerned with clinical outcomes and strategic issues such as 
political advice and whole systems access and those concerned with service operational aspects 
of implementation such as affordability and cost efficiencies and prescribing behaviour change.   
It is clear that patients, manufacturers and some within the service place great value in the fact 
that all medicines access issues in Wales are dealt with in one place with the consistency and 
coherence this brings.  They are also concerned that changes will result in reduced patient 
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access. This is not seen as such an important issue by some operational parts of the service, with 
others not recognising this as an issue at all. 
There was significant support in the service for an expanded medicines management function 
which for many would include greater roles in horizon scanning and commercial arrangements 
(patient access schemes).  There was also considerable support for continuing a centralised 
source of advice to ensure consistency and to avoid ‘postcode prescribing’.  
Conclusions 
The opportunity presented by NICE expanding its HTA work is obvious and welcomed by all, but a 
large majority of interviewees were cautious about the scope and timing of any changes until the 
proposals had worked their way through and implications are clearer.  There is clearly a desire in 
the service for more practical medicines management support and a willingness within 
AWMSG/AWTTC to do more work to support the service. Some areas that were mentioned as 
potential future roles included, amongst others: 
 Horizon scanning for new technologies including budgetary and service change implications. 
 Negotiating and overseeing and managing the implementation of commercial deals and 
arrangements, including outcome measures. 
 Advice to support implementation of HTAs. 
 Policing of medicines management advice to aid performance management of HBs. 
 Development of value-based prescribing guidance where there are multiple options in 
pathways. 
 Expansion of WAPSU to measure clinical outcomes. 
 Re-evaluating old technologies to recommend those now less suitable for reimbursement. 
 Advice and support in changing prescribing behaviour to better implement 
guidelines/indicators. 
This is a significant list of potential developments and the implementation of these will have 
significant implications for the organisation and working of AWMSG/AWTTC. 
2.2 THE CURRENT RELATIONSHIP BETWEEN AWMSG AND NICE IN LIGHT 
OF PLANS TO EXPAND NICE’S APPRAISAL ROLE 
What people told us 
 The implications for AWMSG/AWTTC of the 2019 Voluntary Scheme for Branded Medicines 
and Pricing Access (VSBMPA) and the expanded role of NICE, along with new charging 
arrangements for appraisals are not yet clear.  There is no clear understanding yet of the 
scope and timelines of NICE’s work and what will be left for AWMSG/AWTTC to do. 
 Most agree there will still be some appraisal work necessary and that the local context is 
important.  AWMSG/AWTTC is perceived to offer good value for money in this work.4 
                                                          
4 It is important to note that this perception is based on an impression of value for money, and not on any actual 
data around the budget associated with AWMSG/AWTTC that participants were aware of. We have received some 
information about the costs of the organisation, but this is incomplete and difficult to interpret.  
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 Some suggest partnership or sub-contracting with NICE on appraisals, but this has not gained 
much support. NICE themselves are not yet clear how the future relationship with Wales will 
work, but suggest there will be resources in place to fulfil their new expanded roles. 
 No one yet knows (including NICE) how Wales will respond to the additional roles that NICE 
have been given (as part of the VSBMPA) to develop medicines management. This may 
include enhanced service change guidance and improved management of commercial 
agreements.  These are not currently part of AWMSG’s remit and some consider them to be 
desirable developments that Wales should also implement. 
 The widening of the range of HTAs by NICE may mean that the decision-making process for 
AWMSG/AWTTC in the ones left for them to complete may have to change to bring 
consistency of approach. 
Spectrum of opinion 
Most agree that NICE expanding its role and taking on most if not all HTA work is a positive step.  
Most also agree that current work programmes and relationships should continue for the time 
being.  There is considerable uncertainty about timelines and scope and no one seems to have 
clarity about how Wales will respond to the new roles created for NICE. Respondents were asked 
about charging for HTAs in Wales, but there was no clarity on what should happen. 
Conclusions 
It would seem that a period of watchful waiting is appropriate so that the implications of the 
proposed changes can be examined.  In the meanwhile, it would also seem sensible to explore 
further with NICE and the service how AWMSG/AWTTC could fill some of the gaps created by the 
new VSBMPA agreement in England.  
2.3 THE BALANCE BETWEEN VARIOUS FUNCTIONS CARRIED OUT BY THE 
AWMSG, FOR EXAMPLE BETWEEN APPRAISAL OF NEW MEDICINES AND 
OPTIMISING MEDICINE USE 
What people told us 
 There has already been a recent trend of less work on appraisals and more on medicines 
optimisation.5  This will continue with the VSBMPA changes and is welcomed by all parties. 
Consequently, all parties agree this review is timely. 
 It is difficult to quantify the balance between these functions in the current work 
programme, but there is a recognition that AWMSG/AWTTC is about to approach a tipping 
point when for the first time there will be less HTA activity undertaken than medicines 
management activity. 
 The question has been raised about who drives the AWMSG/AWTTC agenda and the 
frustration felt in some parts of the service in not being able to have an influence over the 
work programme. 
 The value of AWMSG/AWTTC’s ability and flexibility to respond to all Wales issues as they 
arise and to provide independent, strategic advice as and when required.  
                                                          
5 It is important to note that this was based on people’s judgement about the shift in the balance of work as no 
figures are able to quantify this. 
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Spectrum of opinion 
There seems to be a consensus that it is the right time to have a review of these roles and a 
willingness to explore how AWMSG/AWTTC can provide more operational support to the service.  
The main criticisms tended to come from the heads of pharmacy, who would like 
AWMSG/AWTTC to focus more on their day to day challenges and less on issues that affect very 
small numbers of patients or other stakeholders such as the wider public or manufacturers.  They 
would like more control of the agenda. At the same time, there remains a lack of clarity about 
Ministerial strategic aims are translated into the work programme.  Some recognised the value in 
maintaining a strategic arms-length body who provides advice to the Minister. This was not a 
consideration for many in the service.  
Conclusions 
The role of AWMSG/AWTTC is changing and the balance of the work it does will continue to 
evolve, and it may be that this evolution increases in pace. There is a tension between strategic 
and operational demands and the service would like more control of the agenda.  This has 
implications for AWMSG/AWTTC’s current clinical and scientific independence and its ability to 
balance its strategic agenda if it were to be entirely driven by shorter-term service needs. 
2.4 AN UNDERSTANDING OF HOW CURRENT FUNDING REFLECTS THE 
BALANCE OF FUNCTIONS AND WHETHER THIS REFLECTS PRIORITIES NOW 
AND FOR THE FUTURE 
What people told us 
 Linked to objectives and performance, this was not seen by interviewees as an easy question 
to answer. There is uncertainty over how resources are allocated; and a lack of knowledge 
over what the objectives are to allow any judgement on the correct balance. 
 It is very difficult to get any information on how current funding is allocated apart from the 
service’s belief that HTA has been the political priority and the service’s operational needs 
for prescribing guidance, pathway development have been of secondary importance.   
 AWMSG/AWTTC’s ability to flex their resources and be responsive as workloads and 
priorities shift is seen as a strategic strength. 
 There is a view that whatever happens to the relationship with NICE and the balance of 
activities, efforts should be made to retain key staff and skills. 
Spectrum of opinion 
As established earlier, it is very difficult to establish the exact funding resource allocated to 
AWMSG (including its support from AWTTC), and how these resources are deployed across its 
functions. Most people believe the priority has been towards Ministerial advice, particularly for 
HTAs, but have no evidence.  The service believes these priorities need revisiting to enable them 
to benefit from more operational medicines management support.  Outside of AWMSG/AWTTC, 
there is little consideration of the value in having a certain flexibility to how work programmes 
are prioritised and resourced. 
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Conclusions 
There is broad consensus that the priority has been in completing obligatory HTAs and all other 
work has been fitted in around that.  Resources have been allocated accordingly.  The balance of 
work and linked resources is changing.  The extent of these resources and the proportions 
allocated are unknown.  It is also clear that the system as a whole has benefitted strategically 
from the flexibility AWMSG/AWTTC has had to respond to demands, though this is not always 
appreciated by the service. There is certainly value in making resource allocation processes and 
outcomes more transparent.   
2.5 VALUE FOR MONEY AND SCOPE FOR EFFICIENCIES 
What people told us 
 There has been limited access to data which could assist in formally assessing value for 
money, and there are no clear objectives against which to compare outputs and outcomes. It 
may be that the data does not exist in such a way that would facilitate this formal 
assessment. 
 It is acknowledged that NICE provides a “Rolls Royce” service, but it is perceived that Wales 
gets very good value for money compared to similar bodies across the UK (having taken 
account of the first bullet point above).  
 It is likely there will be scope to further reduce the HTA activity over time, though there was 
a majority of people who felt that a reduced capacity for undertaking a number of appraisals 
in Wales needs to be maintained. 
 There is a significant demand from the service for more medicines optimisation work to 
build on the work that is currently done which is valued, notably by WAPSU.   
 The experts within AWTTC are valued and it is perceived that there are enough skilled 
people to manage this change of focus from HTA to medicines management.  
Spectrum of opinion 
Most value the HTA advice, but some believe AWMSG/AWTTC resources would be better 
allocated on more significant matters in terms of budget and service impact as often appraisals 
are for very small numbers of patients. Some feel this would be better strategic value for money.  
There is also a consensus that if NICE do more/all appraisals this should not be duplicated in 
Wales. There are a number of people who question the uptake/action by HBs on the medicines 
management advice they are given and so questioned the performance management of HBs in 
taking advantage of AWMSG/AWTTC’s outputs. 
Conclusions 
With a few exceptions most people believed that AWMSG/AWTTC’s outputs were valuable and 
good value for money.  With proposed changes expanding NICE’s role in a number of different 
ways, there are undoubtedly opportunities to re-allocate resources.  This will require a clear 
understanding of AWMSG/AWTTC’s role and scope, particularly beyond merely providing advice, 
but also a close examination of how HBs influence the agenda and subsequently choose to take 
up advice. 
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2.6 ORGANISATIONAL GOVERNANCE AND SCRUTINY 
What people told us 
 Respondents noted that there is a lack of clarity and consistency when it comes to 
understanding how the governance arrangements of AWMSG/AWTTC operate. 
 It is not clear how their priorities emerge, are agreed or managed – this seems to be done 
informally by the Chair of AWMSG and Clinical Director of AWTTC based on their 
understanding of their purpose in providing strategic advice to the Minister, requests from 
CPO/CMO and what resource they have available after HTAs at any one time. 
 AWMSG/AWTTC place real value on their scientific independence and their ability to 
respond strategically to demands placed upon them. Having said this, they do recognise they 
have to be responsive to service needs. 
 C&V UHB and AWTTC are comfortable in their management arrangements and the formal 
relationship that they have, but is not clear how they and the Welsh Government work 
together to set a strategic programme, agree priorities and changes or manage 
performance.  
 As identified, there are other all Wales posts that are focused on pharmaceutical issues and 
are not part of the AWMSG/AWTTC machinery. We have not explored how they might fit 
within the AWMSG/AWTTC umbrella.  
Spectrum of opinion 
Apart from those who are at the heart of AWMSG and AWTTC (and even here there are different 
views), very few people were able to offer us a clear description of the governance, performance 
management and accountability arrangements.  There is uncertainty and a degree of frustration 
in the service and across other stakeholders that they do not know how the work programme is 
derived and feel unable to influence it.  
There were a few who suggested that AWMSG/AWTTC indicators could be built into the health 
boards performance management process with WG (like joint committees) so that their advice 
was given the right status and its implementation and performance should be managed by WG.  
A couple of respondents mentioned how good AWMSG/AWTTC is in engaging clinical 
stakeholders in producing their guidance and that the relationship with C&V UHB’s clinical 
networks have helped that.  
Conclusions 
Most respondents were unclear about this question, though a few hazarded opinions, none were 
confident.  However, there are two important aspects to consider. The first is public 
accountability for the work of AWTTC and AWMSG. It is currently difficult to explain the 
governance, accountability arrangements and value for money satisfactorily.  Second, the role of 
the Welsh Government in the setting of the agenda: not only to satisfy the above question, but 
also to work through how NHS Wales and the WG will cover the gaps opened up by the new 
VSBMPA arrangements; for example, in the service implications of new medicines and patient 
access schemes and horizon scanning. 
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2.7 EFFECTIVENESS, OUTPUTS AND BENEFITS 
What people told us 
 As described above, the outputs of AWMSG/AWTTC are valued by most in the service.  
There is a debate about the balance and how the service may be better supported in an 
operational sense with many examples given.  An expansion of WAPSU was mentioned 
several times. 
 It was suggested that the value of the outputs could be measured by how well they are 
taken up by HBs.  An example given was prescribing indicators where measures showed a 
mixed performance and suggested they might not be an area of focus for all HBs.   
 Most thought that AWMSG/AWTTC advice is improving clinical outcomes in Wales, however 
it is clear that without a more sophisticated IT system this is very hard to prove.  
 Focusing on medicines optimisation was noted as a key way in which the NHS could be 
supported to derive best value from medicines, and that AWMSG/AWTTC could have an 
enhanced role in this regard.  
 The role of AWMSG/AWTTC in “policing” its own guidance was a point of discussion. 
Spectrum of opinion 
Although some disagreed, most valued the outputs of AWMSG/AWTTC and thought they were 
beneficial. The question of balance was raised again, particularly by HB pharmacists, far less so 
with clinicians who mostly thought the clinical advice to be very good.  There was an emphasis 
from HBs on the need for AWMSG/AWTTC to provide more effective advice that would enable 
them to make efficiency savings. Very broadly, the clinical advice on practice variation and best 
practice was valued by clinicians and even without outcome measures was seen to be beneficial.  
On the other hand, prescribing advice that enabled reductions in prescribing volume, cost and 
scope to produce efficiencies was most valued by HB pharmacists. There were a small number of 
individuals across this broad divide who could see enhanced and substantively new roles 
(especially for WAPSU) that could be developed in respect of two areas. Firstly in respect of 
Prudent Healthcare (for example, linking the pre-existing data on use of medication with the 
patient pathway to provide value-based evidence on effectiveness); and secondly with regard to 
quality (for example, tracking low volume medication post-HTA through to the clinical outcome 
phase to help the service understand when medicines are providing value, and when they are 
not).   
There was a split of opinion when respondents were asked about AWMSG/AWTTC having more 
of a policing function for its guidance.  Some thought it might help, others were concerned that it 
was out with their terms of reference and might impact upon their clinical impartiality and 
relationships.  Some HBs did not want any outside interference in their operational roles 
Conclusions 
We found very few examples of where the effectiveness of AWMSG/AWTTC outputs were being 
measured. This is seen as desirable but expensive and requiring better IT infrastructure. There 
are some limited but positive developments in WAPSU’s relationship with the NHS Wales 
Informatics Service (NWIS) which would permit AWMGS/AWTTC to track the clinical outcomes of 
medicines (and the value-based effectiveness of them) when they are deployed within the 
service. AWMSG/AWTTC sees its role as providing advice, not implementation and not 
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outcomes.  It is obvious that the current outputs are valued, but that the service would like a 
greater emphasis placed on supporting them operationally.  There are many suggestions for this.  
However, there is also a danger in being led by the service alone as some suggested that where it 
didn’t suit them HBs did not action guidance and their performance is mixed.  Although some 
could see a change in the AWMSG/AWTTC role to one that included overseeing the 
implementation and use of its guidance this was generally resisted by HBs.  Another way of 
improving the uptake of guidance suggested was to feed it into the joint performance 
management meetings between HBs and WG.  
2.8 AWMSG’S CAPACITY AND CAPABILITY, BOTH IN TERMS OF STAFFING 
AND LEADERSHIP, TO RESPOND EFFECTIVELY TO FUTURE DEMANDS AND 
THE CHANGING ENVIRONMENT 
What people told us 
 Some in the service have referred us to how the management of strategic medicines issues 
works in England where NICE and NHS England play different parts, for example in 
affordability considerations.  It is recognised that the situation in Wales is quite different 
with no separate NHS Board and potentially, therefore, a gap in capability and leadership. 
 There are a range of potential changes on the horizon.  There is also a clear willingness to 
review the functions of AWMSG/AWTTC and a recognition that HTA activity will continue to 
decline.   
 It is also clear that the knowledge, skills and experience of the AWTTC staff who support 
both HTA and Medicines Optimisation work are valued.   
 As identified above, the leadership structure for AWTTC and AWMSG is not clear, 
particularly in relation to the governance roles of C&V UHB and the Welsh Government. 
 Again, as previously discussed, the importance of AWMSG/AWTTC having independence and 
flexibility to respond to strategic priorities might not sit comfortably with the service driving 
the agenda to support day-to-day operational issues, though it is recognised by all parties 
that increased responsiveness is desirable.  
 Linked to this is the importance of AWMSG/AWTTC stakeholder engagement at a strategic 
level.  This includes patient groups, the public, manufacturers and other industrial players as 
well, crucially, as providing political support.  
 Finally, there is the importance of whole system leadership including consistency and 
coherence of policy and advice.  Almost all respondents valued this role and did not want a 
return to individual HBs deciding common medicines issues separately.  
Spectrum of opinion 
Most of these strategic issues were not recognised or discussed with interviewees from HBs, 
their focus was normally on operational support.  Where they were recognised their value was 
noted.  Most agreed there was a potential leadership gap, but couldn’t put their finger on where 
it was or why they felt that.  This was compounded by a lack of knowledge of accountabilities.  
Most felt that there were adequate capabilities to cope with a future agenda, provided a smooth 
transition in the balance between HTA and medicines management work is well managed.  There 
was almost universal support for increasing capabilities for horizon scanning along with support 
Review of AWMSG – Report for Welsh Government · May 2019                Page 14 
for the implications of new technologies.  Also, for improved and consistent management of new 
commercial arrangements. 
Conclusions 
In arriving at conclusions about the future of AWMSG/AWTTC it is important to recognise not 
just the increasing demands of the service for operational support, but also the important 
strategic role they play.  It will be necessary to consider how the changes to NICE impact on HTA 
capability, but also important to maintain a balance of strategic and operational advice.  A bigger 
question again will be how much do AWMSG/AWTTC move to support the development of 
implementation guidance along with resources and processes to support it.  Finally, there 
appears to be a demand to make the leadership and accountabilities clearer and more 
transparent along with improving the processes and opportunities to influence the agenda.  
Though we have noted the potential limitations of this influence if AWMSG/AWTTC is to also 
retain a strategic role and capability.  
2.9 SUMMARY 
It is clear from the findings, that many stakeholders have a broadly positive view of how 
AWMSG/AWTTC functions. That said, there is a clear evidence-base that change is needed to 
ensure that the organisation is improved and future-proofed as the world in which it operates 
becomes more challenging and complex. These issues are further discussed in the next chapter.  
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3.  AREAS FOR FURTHER CONSIDERATION  
In order to bring these findings together, this section outlines ‘areas for further consideration’ in 
five specific categories that have emerged from the evidence gathered during the study. They are 
offered as points for discussion and each of them is followed by a set of ‘test questions’ designed 
to help AWMSG/AWTTC, the Welsh Government, the NHS, C&V UHB, industry and the other key 
stakeholders to think about how further work and development in these areas should be 
focused. 
Future-proofing the findings 
It is important to recognise that the areas for further consideration and associated test questions 
below need to be considered in the context of the external environment and uncertainties in 
which AWMSG must operate in the future. Four strategic forces are central here, but have 
considerable degrees of uncertainty attached to them: 
 The future needs and demands of the NHS in Wales for pharmaceuticals in the light of 
social, epidemiological and clinical trends that will take place in Wales 
 The pharmaceutical developments that will come on stream in years to come and the 
clinical and cost implications of those developments. 
 The resource position of the NHS in Wales (which is likely to involve low annual growth in 
financial resources which are less than the historic average for the NHS as a whole) and the 
need to finance additional pharmaceutical spending for these new products under the 
auspices of the VSBMPA arrangements. 
 The future range and volume of activities that will be undertaken by NICE and which will 
impact on Wales. The uncertainty about the future activities of NICE have already been 
discussed in Chapter 2.  
Identified areas for further consideration 
We have identified a number of key areas for consideration and discussion and these need to be 
seen in the context of the findings of our study and the four strategic trends referred to above. 
These five areas are as follows: 
1. Role and strategic direction  
2. Working with the NHS in Wales to help drive quality improvement 
3. Accountability and governance arrangements 
4. Organisational arrangements and resourcing 
5. Leadership and change management 
3.1 ROLE AND STRATEGIC DIRECTION  
Chapter 2 of our report discussed the roles of AWMSG/AWTTC and the views, from many people, 
that there should be change in the balance of roles with a shifting focus away from HTA work and 
towards other areas of activity focused on improving the quality of care which include among 
others, medicines management, medicines optimisation, and horizon scanning. This issue is 
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particularly germane given the uncertainty about the activities of NICE and the potential impact 
of the other three strategic forces referred to above. 
However, such changes do not necessarily happen by accident but need to be planned and 
suitably managed. If this is not done, the organisation may drift in an unintended direction.  
Test questions to be addressed 
How should the balance of various roles of AWMSG/AWTTC change over time to ensure 
the right emphasis is placed on the quality of care? 
What should be the pace of change of any shift in strategic direction by AWMSG/AWTTC? 
How should AWMSG/AWTTC (and its key stakeholders) make determinations about the 
right balance of its functions?  
In the light of the proposed changes from NICE, what represents the right balance 
between the strategic and more operational role of AWMSG/AWTTC? 
 
ANNUAL PRIORITY SETTING AND MANAGEMENT 
Linked to the above, and to ensure the strategic direction of the organisation is achieved, there 
needs to be a process of annual priority setting which shows, in a transparent manner, what the 
organisation aims to try and achieve over the next twelve months and how those activities align 
with the strategic direction.  Although such a process does exist within AWMSG/AWTTC, it is not 
sufficiently clear to stakeholders to instil confidence in it. Hence, there is a need to develop a 
process which indicates, in a transparent and accountable manner, what the annual priorities of 
the organisation are and how delivery of these priorities is to be managed.   
Test questions to be addressed 
How should the process of annual priority setting by AWMSG/AWTTC be enhanced and 
linked to its strategic direction? 
Which stakeholders/organisations should contribute to the process of annual priority 
setting? 
What role should health boards play in setting these priorities given the pressures on their 
own plans, and the budgets that influence these? 
How should operational activities be managed to ensure priority activities are achieved in 
terms of outputs and costs? 
3.2 WORKING WITH THE NHS IN WALES TO HELP DRIVE QUALITY 
IMPROVEMENT 
The findings of chapter 2 of this report were that the way in which AWMSG/AWTTC and the NHS 
in Wales works were, in general, seen to be quite good although improvements are always 
possible. However, there was a view expressed that AWMSG/AWTTC needs to help support the 
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drive towards value-based care, and that it can only do this if there is an improvement in the 
extent to which Health Boards in Wales took on board and applied the recommendations and 
guidance from AWMSG/AWTTC. Various means of doing this were discussed, including the 
provision of statutory powers for AWMSG/AWTTC to enforce its recommendations. However, 
one simpler improvement is a suggestion that AWMSG/AWTTC should interface and 
communicate with Health Boards at a higher level, than has traditionally been the case, in order 
to “deliver the messages” at the highest managerial level. This implies a strengthened 
communication and engagement between AWMSG/AWTTC staff and Board members of the 
Health Boards. 
The purpose of such enhanced engagement would be to allow for AWMSG/AWTTC to support 
the service more effectively in improving quality. There is scope for increasing the amount of 
work that AWMSG/AWTTC explicitly does in respect of medicines optimisation that could help 
the service to understand more about the clinical outcomes being achieved, especially if WAPSU 
and NWIS forge closer partnership to bring extant datasets on the effectiveness of medicines 
together with data on the patient pathway. This closer alignment on issues of medicines 
optimisation and clinical outcomes could give AWMSG/AWTTC an enhanced set of roles in using 
data to help drive quality improvement, and to support the service in the need to deliver more 
Prudent and value-based healthcare in Wales. 
Test questions to be addressed 
How should AWMSG/AWTTC engage more robustly at board level with Welsh Health 
Boards? 
What should be the dialogue and means for such engagement? 
How should AWMSG/AWTTC more effectively support the drive to improving quality 
across NHS Wales, and deliver more prudent and value-based healthcare?  
How would AWMSG/AWTTC organise and resource such enhanced activities? 
3.3 ACCOUNTABILITY AND GOVERNANCE 
In chapter 2 of our report we have reported some concerns on the existing accountability and 
governance arrangements of AWMSG/AWTTC. Very few people were able to offer us a clear 
description of the existing governance, performance management and accountability 
arrangements in the organisation. Hence consideration needs to be given to having a definition 
of the accountability and governance arrangements of AWMSG/AWTTC which is transparent and 
which has broad based support from all interested parties.  
Test questions to be addressed 
How should existing accountability and governance arrangements for AWMSG/AWTTC be 
enhanced in order to provide clarity for all key stakeholders? 
What new lines of governance and accountability need to be set? 
Who should be the participants in this new accountability and governance process? 
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How should this new process relate to how priorities for AWMSG/AWTTC are set and 
managed? 
3.4 ORGANISATIONAL ARRANGEMENTS AND RESOURCING 
Changes made in relation to the areas described above will have implications for the ongoing 
organisational arrangements of AWMSG/AWTTC. It cannot just be assumed that the existing 
organisational arrangements will remain unchanged and changes may be needed in order to 
deliver the changes in strategic direction, accountability, communications etc. These implications 
could involve a wide range of organisational matters including: 
 internal organisational structures and management reporting,  
 reporting arrangements,  
 deployment and management of staff resources, 
 staffing numbers and skill mix,  
 training and development needs, and 
 operational budgets. 
Test questions to be addressed 
What might be the implications of changes in the “modus operandi” of AWMSG/AWTTC 
for its organisational arrangements? 
How might changes in these organisational arrangements be made and over what 
timescale? 
How well does the current skill mix of staff within AWMSG/AWTTC meet the requirements 
of the organisation as it develops? 
How does the organisation re-balance its functions in order to meet the increasing 
demands placed upon it by the service, but also meet it strategic duties as required by the 
Cabinet Secretary for Health and Social Services? 
AVAILABILITY OF MANAGEMENT INFORMATION 
We have already referred to the paucity of management information in AWTTC particularly 
around the difficulties of obtaining information on issues such as such as use of resources, 
volume of activities, outputs etc. As a consequence, we have commented that any objective 
assessment of matters such as efficiency, effectiveness, VFM is just not possible in the absence of 
such data.  
Having a minimal level of robust management information is essential, not just for efficiency and 
value for money but for other matters such as strategic direction, operational planning, quality 
control, and ‘client’ satisfaction (whether this is Cardiff and Vale University Health Board as its 
host organisation, or the Welsh Government, as sponsoring body). 
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Test questions to be addressed 
What management information should be routinely produced by the organisation? 
By which methods is such information to be produced? 
3.5 LEADERSHIP AND CHANGE MANAGEMENT  
All of the above areas have change implications for the organisation. To ensure the necessary 
changes go smoothly some form of change management is required which is driven by having a 
clear leadership focus.  
At the time of writing, processes are underway to make new appointments to the posts of Chair 
of AWMSG and Clinical Director of AWTTC. The appointees to these posts are likely to be the 
ones who will lead any future change process. Hence, this provides an opportunity to appoint to 
these positions people who the necessary leadership skills as well as the other skills needed. 
Test questions to be addressed 
What are the leadership and change management skills that will be needed in 
AWMSG/AWTTC in the future? 
How are these skills to be identified in possible appointments to the posts of Chair and 
Clinical Director? 
How are these skills to be developed in other senior managers in AWTTC? 
 
AWMSG/AWTTC’S INDEPENDENCE 
Finally, it is important to reflect on the independence that AWMSG/AWTTC has. As a Welsh 
Government Sponsored Advisory Body, it is not independent of the Welsh Government, but does 
act ‘independently’ in two key aspects. The first – that of their clinical and scientific 
independence – was respected and valued by all stakeholders, and one that that needs to remain 
as the organisation responds to the changing agenda. The second – in exercising operational 
independence and strategic control over their work programme – was less clear, and contested.  
NHS colleagues, in particular, called for more transparency in prioritisation decisions, and a 
greater stake in the development of AWMSG/AWTTC’s agenda. For all parties, there was a plea 
to be able to see how Welsh Government’s priorities are translated into their annual work 
programme. At the moment there is a feeling that these priorities emerge and are decided by 
AWMSG/AWTTC themselves rather than as part of an open and strategic planning process. 
Test questions to be addressed 
How do Welsh Government’s priorities for service change and improvement get 
translated into AWMSG/AWTTC’s annual work programme? 
What process should be employed in order to create greater transparency in the 
development of AWMSG/AWTTC’s work programme? 
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How should AWMSG/AWTTC be engaged in Welsh Government’s strategic planning 
processes? 
3.6 CONCLUSIONS 
Taken together, this section represents a potential work programme for moving AWMSG/AWTTC 
from its current mode of operation to a new one, in line with the comments made by 
respondents. In doing this, we have posed a number of critical ‘test questions’ which, we believe, 
need to be addressed when considering the future role of AWMSG/AWTTC against the current 
AMWSG Constitution and the Roles and Responsibilities within. It may be the case that these are 
deemed to still be ‘fit for purpose’, but given the scale and scope of the feedback received in this 
exercise, it is likely that they will need to be amended and updated in certain respects. 
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APPENDIX | ABOUT THE WELSH INSTITUTE FOR HEALTH AND SOCIAL CARE 
The Welsh Institute for Health and Social Care (WIHSC) is part of the University of South Wales.  
Since 1995, WIHSC has existed to bridge gaps between academia, policy and practice. 
STRATEGIC INTENT AND VISION 
The strategic intent of WIHSC is to be a key player in informing and influencing the 
implementation of evidence-based health and care services across the statutory, voluntary and 
independent sectors. WIHSC has a national reputation for impact as a leading health and care 
policy research institute, which is built on a robust financial platform derived from the delivery of 
excellent academic research, evaluation and consultancy. We recognise that the following are 
critical factors in us delivering the strategic intent and vision: 
 A reputation for excellence in research, evaluation and impact amongst key stakeholders – 
whether in government, health and care services, the media or the public 
 An established credible staff resource including the collection of experts6 who can be 
utilised to achieved the vision 
 Achieving a measure of academic impact in order secure the role of the institute within the 
relevant research frameworks of the University and beyond 
 A strong, and growing, self-financing status based on healthy revenues 
PRIORITIES 
WIHSC has five priority areas reflecting our current research strengths and aspirations for new 
areas of work and influence. 
1. Prevention of escalating need 
 Understanding the nature of services and how they can offset further (more costly) 
interventions. 
This is best demonstrated in our recent work evaluating the impact of the Integrated Care Fund 
‘Stay Well@Home’ programme which runs across the Cwm Taf region and is designed to reduce 
escalating need through the front door of A+E.  
In addition our action research study for a third sector mental health charity has helped to ensure 
that there is now core funding for Step by Step, a service preventing the further escalation of issues 
for single homeless people presenting to the local authority with moderate mental health problems.  
2. Integration of health and care 
 Analysing the ways in which the public, third and independent sectors are increasingly 
aligning to provide health and care services. 
                                                          
6 WIHSC enjoys the support of three Visiting Professors and two Visiting Fellows. Professor Alka Ahuja (Consultant Psychiatrist in 
Child and Adolescent Mental Health Services in Aneurin Bevan University Health Board) has been a part of the WIHSC team for 
many years. In addition, we have recently developed and appointed a WIHSC Expert Reference Group. Its members are Tony 
Garthwaite (Visiting Professor), Malcolm Prowle (Visiting Professor), Heulwen Blackmore (Visiting Fellow), Jeremy Felvus (Visiting 
Fellow) and Margaret Provis. The purpose of the ERG is to help WIHSC to realise its strategic intent and vision, and act as a critical 
friend and to review progress towards achieving is objectives. 
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Evidence of this comes from our recent study on the workforce integration of health and social care 
across Wales, Working for a Shared Common Purpose. The study was commissioned by UNISON 
Cymru Wales, and endorsed by the Cabinet Secretary for Health and Social Services at its launch.  
Further, we supported organisations and public bodies through the Strengthening the Connections 
programme which provided networks, events and opportunities for collaborators to share 
experience and learn lessons about what works, where and why. 
3. Co-produced care and outcomes 
 Reflecting on the changes in public services brought about by user- and citizen-led services 
and forms of support to deliver outcomes for people. 
Over many years WIHSC has run a series of citizens’ juries which have provided a forum within which 
key issues of public policy can be discussed, debated and to some extent resolved. Most recently this 
focused on the crucial issue of Antimicrobial Resistance and Stewardship and the role of citizens. 
Furthermore, our Health Foundation-funded research study to understand the impact of the 
Prudent Healthcare principles in practice focused in part of the way in which co-production has 
become (or has not become) integrated within the delivery of healthcare services. 
4. New models of care 
 Providing an evidence-base upon which new modes of ‘delivery’ – whether new pathways, 
new teams, new technology, or new medicines – will improve outcomes. 
Service innovation has been at the heart of our work since WIHSC’s inception. Working in 
partnership with the Swansea Centre for Health Economics, our UK-wide study of the impact of Eye 
Clinic Liaison Officers is one such study. We identified an evidence-base which has influenced the 
further implementation of this role within ophthalmology outpatient clinics.  
Our study reviewing the approach to Horizon Scanning for New Medicines has impacted on the way 
in which the quartet of key stakeholders – policymakers in government, NHS organisations, the 
national therapeutics authority and the industry – will work together. 
5. Value-based care across the whole pathway 
 Detailing the impact that new models of care have for pathways and the value of those 
pathways, expressed in financial terms. 
Understanding the ways in which the Third Sector have provided new pathways of care in many 
different areas across health and social care is a key part of our portfolio of projects. The Discussion 
Paper we wrote about this provides a useful insight into what is happening within the sector. 
New pathways in the way services have moved from hospital to community settings is in line with 
principles of prudent healthcare and the approach of all the devolved administrations across the UK 
governments. Our work on Community Cardiology is noteworthy in this regard. 
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